Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use
Open Access
Abstract
The COVID-19 pandemic has highlighted the need for efficient vaccine platforms that can rapidly be developed and manufactured on a large scale to immunize the population against emerging viruses. Viral-vectored vaccines are prominent vaccine platforms that have been approved for use against the Ebola virus and SARS-CoV-2. The Newcastle Disease Virus is a promising viral vector, as an avian paramyxovirus that infects poultry but is safe for use in humans and other animals. NDV has been extensively studied not only as an oncolytic virus but also a vector for human and veterinary vaccines, with currently ongoing clinical trials for use against SARS-CoV-2. However, there is a gap in NDV research when it comes to process development and scalable manufacturing, which are critical for future approved vaccines. In this review, we summarize the advantages of NDV as a viral vector, describe the steps and limitations to generating recombinant NDV constructs, review the advances in human and veterinary vaccine candidates in pre-clinical and clinical tests, and elaborate on production in embryonated chicken eggs and cell culture. Mainly, we discuss the existing data on NDV propagation from a process development perspective and provide prospects for the next steps necessary to potentially achieve large-scale NDV-vectored vaccine manufacturing.Keywords
Funding Information
- National Research Council of Canada (NRC) (PR-013.1, CRC-240394)
- Canada Research Chairs (PR-013.1, CRC-240394)
- MITACS Globalink Graduate (PR-013.1, CRC-240394)
This publication has 142 references indexed in Scilit:
- Newcastle Disease Virus-Vectored Rabies Vaccine Is Safe, Highly Immunogenic, and Provides Long-Lasting Protection in Dogs and CatsJournal of Virology, 2011
- A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogenVaccine, 2011
- Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody responseVaccine, 2010
- Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturingVaccine, 2010
- Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1Vaccine, 2010
- Immunization of Primates with a Newcastle Disease Virus-Vectored Vaccine via the Respiratory Tract Induces a High Titer of Serum Neutralizing Antibodies against Highly Pathogenic Avian Influenza VirusJournal of Virology, 2007
- Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogensProceedings of the National Academy of Sciences, 2007
- Newcastle Disease Virus-Based Live Attenuated Vaccine Completely Protects Chickens and Mice from Lethal Challenge of Homologous and Heterologous H5N1 Avian Influenza VirusesJournal of Virology, 2007
- Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle diseaseProceedings of the National Academy of Sciences, 2006
- Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenzaProceedings of the National Academy of Sciences, 2006